Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 3/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28577422 | 0.84 | MEN1 (0.65) | NHERF1NPC1MEN1KMT2A | |
| SCHEMBL6357069 | 0.79 | SERPINE1 (0.69) | CDK2IGF1RMET | |
| SCHEMBL20567521 | 0.79 | STING1 (0.64) | NHERF1NPC1MEN1KMT2AIGF1R | |
| SCHEMBL8258111 | 0.79 | MEN1 (0.65) | NHERF1NPC1MEN1KMT2A | |
| SCHEMBL29452910 | 0.79 | MEN1 (0.65) | NHERF1NPC1MEN1KMT2A | |
| SCHEMBL397948 | 0.78 | CFTR (0.64) | NHERF1 | |
| SCHEMBL30695128 | 0.78 | NHERF1 (0.65) | NHERF1NPC1MEN1KMT2A | |
| SCHEMBL29176615 | 0.78 | NHERF1 (0.65) | NHERF1NPC1MEN1KMT2A | |
| SCHEMBL1308632 | 0.78 | GRIK1 (0.72) | GRIK1MEN1KMT2A | |
| SCHEMBL27075304 | 0.78 | NPC1 (0.68) | NHERF1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | NHERF1 764/4885GRIK1 2986/4885F7 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.